Posted by Michael Wonder on 30 Jan 2024
European Commission authorises GSK’s Omjjara (momelotinib)
29 January 2024 - Indicated in both newly diagnosed patients and those previously treated with existing standard of care.
GSK today announced the European Commission granted marketing authorisation for Omjjara (momelotinib), a once a day, oral JAK1/JAK2 and activin A receptor type 1 inhibitor.
